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LETTER from DIRECTOR
Dear Colleagues,
The 2003 Children’s Mercy Hospital
Cancer Center Annual Report focuses
on a cancer that extends across all ages
of children and adults. Acute Myeloid
Leukemia (AML) occurs in newborns,
as well as the elderly. It is a cancer
that both pediatric and adult
oncologists struggle with on a daily
basis. It remains one of the most
difficult cancers to treat for children.
Until the past decade, cure rates
ranged from 20-25 percent. Today,
cure rates have improved
dramatically to almost 50
percent. However, AML
carries the worst prognosis
among all childhood
cancers. As you will note
in this report, therapy over
time has evolved with
success, but with great cost.
In order to improve cure
rates, therapy has become
more intense and children
who receive this treatment
will experience prolonged
periods of immune suppression. This
places them at great risk for infection
which is a leading cause of treatmentrelated mortality in the pediatric
population. It’s important to
recognize, however, the significant
advances in supportive care. Lessons
from similarly immune suppressed
patients, ie, those undergoing bone
marrow transplant, show that
protective environments, constant
monitoring, and rapid initiation of
antibiotics and evaluations will
improve the survival of these children.
In light of these facts, Children’s Mercy

Hospital constructed a specially
designed patient care unit, 4 Henson,
for all children undergoing
chemotherapy. This unit utilizes the
most advanced technology to protect
children from infectious organisms in
the environment, most notably fungi.
Four (4) Henson is fully hepafiltered to
reduce the risk of infectious
complications for these children while
still permitting them the freedom to
leave their rooms. For all the children
with cancer, this environment
combined with multi-disciplinary care
of the oncology care team
provides a safe and
comfortable place for them
to be during their difficult
therapy. This multidisciplinary approach,
outlined in this report,
provides the expertise of
many disciplines and
specialties to provide a
synergistic care that far
exceeds the sum of its
parts. This is the special
aspect of the care received
at Children’s Mercy Hospital. We
invite you to review the 2003 Annual
Report which focuses on AML and
illustrates the services and state-of-theart care available for the children
diagnosed with cancer in our region.

Alan S. Gamis, MD, MPH
Director of Oncology
Chair, CMH Cancer Care Committee

LETTER from PRESIDENT/CEO
Dear Colleagues,
Children’s Mercy Hospitals and
Clinics continued its growth
during the past year, with
expansion of our facilities at both
Children’s Mercy Hospital in
Kansas City and Children’s Mercy
South in Overland Park. We also
opened a new location for
specialty clinics and urgent care,
Children’s Mercy Northland, and
all three locations continue to
experience significant increases in
the volume of patients
seen and the range of
services offered.
Our Division of
Hematology/Oncology
continued its growth and
commitment to excellence
during the past year, as
well. Our program
continues to be recognized
by the American College of
Surgeons as a national pediatric
cancer center, and Children’s
Oncology Group, an NIH funded
research consortium, recognizes
Children’s Mercy Hospital as one
of the largest pediatric cancer
centers in the country. In 2003, the
cases of newly diagnosed oncology
patients rose to 126, among the
highest this program has seen.

This 2003 Annual Report
highlights Acute Myeloid
Leukemia (AML), a more
aggressive form of childhood
leukemia which affects children of
all ages. Approximately 800 new
cases in children are diagnosed in
the United States each year, with a
median patient age of 4.5 years.
Children diagnosed with AML
continue to see poor survival rates
and Children’s Mercy Cancer
Center is dedicated to seeing these
rates improve through our
collaborative efforts, also
highlighted in this report.
We hope you will take a
few moments to review
our 2003 Cancer Center
Annual Report to learn
more about how we
continue to dedicate
ourselves to caring for
children with cancer and
their families and to
finding new and better ways to
provide treatments and cures.
Sincerely,

Randall L. O’Donnell, PhD
President & Chief Executive Officer

DIVISION of HEMATOLOGY/ONCOLOGY
The Division of Hematology/Oncology at
Children’s Mercy Hospitals and Clinics
is dedicated to providing comprehensive
care to children with cancer and blood
disorders. Our goal is to provide this
care in a family-centered care
environment in an effort to promote
health and well being. The division is
divided into two sections: the Section of
Oncology and the Section of
Hematology. The Division Chair is
Gerald Woods, MD. The Division
Manager is Sue Stamm, RN, MHA, CPNP.

•

Family Centered Care Core Elements
Supported by Division
 Respect the dynamics of the
patient/family
 Acknowledge and empower the
strength of the patient/family
 Provide choices to patients/
families, when available
 Provide unbiased and accurate
information
 Provide emotional, financial, and
spiritual support
 Provide flexibility
 Support a collaborative
relationship between the patient/
family and the health care team.
 Empower the family to be a
partner in the care of their child.

by utilizing umbilical stem cells,
matched-related donor cells, and
matched-unrelated donor cells.
There is a national Bone Marrow
Transplant Consortium which is
centered at Children’s Mercy
Hospital and the chairperson is
Dr. Alan Gamis.
The Oncology Service-DirectorAlan Gamis, MD: dedicated to
the treatment of malignant
disorders. In 2003 this service
diagnosed 126 new cases of
cancer. The Oncology Service
treats patients in accordance
with clinical trials under the
guidance of the Children’s
Oncology Group.

The Section of HematologySection Chief-Gerald Woods, MD
• The Sickle Cell Disease ServiceService Director-Gerald Woods,
MD: offers specialized care for
the unique diagnostic and
treatment needs of children and
adolescents diagnosed with
sickle cell disease. These
patients and families are
confronted with episodes of
acute pain, life limiting chronic
pain, and other long term
sequelae related to this
devastating disease.
• The Regional Hemophilia
Center-Center Director-Brian
Wicklund, MD: supports seven
sites in a five-state region to
provide comprehensive
treatment for both adult and
pediatric patients with bleeding
disorders. In addition, this
service supports the diagnosis

The Section of OncologySection Chief-Alan Gamis, MD:
• The Bone Marrow Transplant
Service-Interim Director-Alan
Gamis, MD: provides
hematopoeitic stem cell rescue to
patients receiving myelosuppressive or ablative therapy
which requires stem cell rescue.
Stem cell rescue is accomplished
3
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and treatment of coagulation
and/or thrombosis disorders.

Children’s Mercy Hospital currently
supports three fellowship positions.

Children’s Mercy Cancer Care
Committee
The Children’s Mercy Hospital Cancer
Care Committee is a standing medical
staff committee that provides oversight
of the oncology services. The committee
is chaired by the section chief for the
Section of Oncology and has both
physician and non-physician
representation (see member listing). It is
comprised of a multidisciplinary team of
physicians, staff, and other discipline
from across the institution. The
committee meets quarterly and reviews
patient acuity, program services and
quality initiatives, and determines
quality improvement needs and
opportunities related to pediatric cancer
prevention, diagnosis, treatment, and
outreach. The committee functions in
accordance with the American College of
Surgeons’ accreditation standards.

Case Management
Empowering........is the goal of the nurses
supporting case management in
advanced practice or expanded nursing
roles. The advanced practice/nurses in
expanded roles include nurse
practitioners, clinical nurse specialists,
and nurse clinicians. The Bone Marrow
Transplant Service utilizes two RN
Program Coordinators for their case
management. Each nurse is partnered
with an attending MD to comprise a
primary team for the children and family
to identify. These nurses coordinate
every aspect of the patient’s care
throughout treatment and during posttreatment follow-up. The case manager is
the primary contact person for the
patient and the family. Patient/family
satisfaction was measured at several
periods following the implementation of
the case management model and
satisfaction scores ranked high.

Pediatric Hematology/Oncology
Fellowship Program
The fellowship program at Children’s
Mercy Hospital trains the future
pediatric hematology/oncology
specialists. This program requires
intense clinical and research training for
a minimum of three years. Each fellow
at Children’s Mercy Hospital enters the
fellowship program as a fully trained
pediatrician. The first 18 months are
dedicated primarily to clinical care and
becoming familiar with procedures and
standards of practice. The subsequent
18 months are dedicated heavily to
clinical and laboratory research. The
Division of Hematology/Oncology at

When the diagnosis of AML is
confirmed, the case manager joins the
physician in preparing and delivering a
discussion with the family about the
disease and the recommended plan for
treatment. This information is repeated
by the case manager through a series of
individualized discussions, written
educational material, handouts regarding
the therapy plan, as well as, a Caregivers
Oncology Handbook. The education,
consultation and support given by the
case manager at this crucial time ensures
that the patient and family are well
informed. Additional diagnostic and
baseline studies, consultations and
4
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outside expert reviews, if indicated, are
personally coordinated by the case
manager.

and an oncology physician through our
main hospital operator, 816-234-3000.
Throughout and following therapy, the
child with AML may require multiple
providers and services from a variety of
disciplines and community agencies.
The case manager can negotiate the
various systems to gain the necessary
services while assuring that the child
does not get lost in the system.
Insurance companies, home health
agencies, and multiple other support
and ancillary services are coordinated
by the case manager while ensuring that
the maximum coverage benefits are
utilized. Ongoing contact with the
referring pediatrician, the child’s school
and other providers ensures that those
who participated with the child prior to
the diagnosis of AML continue to be
involved and informed throughout
therapy. Despite the life-disrupting and
life threatening nature of AML, families
and children display remarkable
resilience with the guidance, education
and coordination provided by the case
manager.

Once the treatment plan has been
established, the case manager walks
through the phase of treatment or
“roadmap”, line by line with the patient
and family members. Knowing what
medications are due, what side effects
may occur and how they will be
monitored, strengthens the family’s
participation in their child’s illness. The
treatment plan is communicated to the
staff who are directly involved with the
child to ensure continuity of care both in
and outpatient.
During therapy, the case manager
oversees every aspect of the child’s care.
He/she provides written reminders about
follow up appointments and lab work,
clarify medications that may need to be
administered at home, reiterate
guidelines of when to seek medical care
and when the child may attend school,
church and social activities. The
anticipatory guidance provided
empowers the parents to resume their
natural role with their child despite the
AML, while meeting their own needs
and that of their families and their
employers. Those case managers
practicing in advanced practice roles
may also perform physical examinations,
prescribe medications, and perform
procedures within their credentialing
privileges. The case manager is available
by telephone and email to listen to the
families concerns and answer their
questions. Evening and weekend triage is
provided by an advanced practice nurse

Physician’s Assistants
Physician’s Assistants (PA) are
dedicated primarily to the Bone Marrow
Transplant Service. Their role is
supporting the day-to-day management
of these patients, both inpatient and
outpatient, in partnership with an
attending MD. Program Coordinators
work in close partnership with both the
MD and PA to ensure the care is well
coordinated.
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The Children’s Mercy Cancer Center
Cancer Care Conferences
The Children’s Mercy Cancer Center
Cancer Care Conferences provide
opportunities for a multidisciplinary
discussion regarding newly diagnosed
patients, recurrent/relapsed patients, and
unusual pediatric cancer cases. All
patients diagnosed with a childhood
cancer are discussed at these meetings.
The conference consists of a review of
the patient’s history, physical findings at
diagnosis, laboratory values, radiology
exams, surgical interventions, and
pathological findings. This diagnostic
review is followed by a thorough review
of the potential treatment options,
current therapy available, response to
therapy, if applicable, and anticipated
prognosis. Medical specialists from
oncology, surgery, pathology, radiology,
radiation oncology, neurosurgery,
orthopedic surgery, endocrine,
psychology, and dentistry are
represented. In addition, non-physician
representatives include: advanced
practice nursing, physician’s assistants,
hospital management/administration,
social workers, child life specialists,
chaplain, dieticians, and staff nurses.
These cancer conferences are conducted
in accordance with the American
College of Surgeons’ accreditation
standards.

Quality Improvement for 2003
• Assessment of antibiotic therapy
used for Fever and NeutropeniaOncology Services
• Assessment of thoracoscopy for
the diagnosis and treatment of
malignancies-Surgery Services
Psychosocial Services
 Parent-to-Parent Program:
designed to connect parents who
have been through the cancer
experience with parents of a
newly diagnosed child with
cancer. In addition, this program
offers support groups on a
weekly basis facilitated by parent
volunteers under the oversight of
a social worker.
 Social Work and Community
Services: there are five full-time
social workers dedicated to the
Division of Hematology/
Oncology. The primary focus of
this team is to assist the patient
and the family in understanding
the impact the diagnosis of
cancer will have on their family
dynamics and life style.
 Bereavement Support Group/
Program: this program is offered
to parents who have experienced
the loss of a child. The program
includes staff contacts to
parents/family members during
significant events such as
birthdays, anniversary date for
the death of the child, an annual
memorial service, and the
composition of a memory book.

American College of Surgeons
Requirements for Quality Assurance
Site Specific Studies for 2003
• AML-Oncology Services
• Neuroblastoma-Surgery Services
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Child Psychologist: a full-time
psychologist provides support to
the patient, parents, and siblings
of those diagnosed with
childhood cancer.
Chaplaincy: a full-time chaplain
supports the spiritual needs of
the patients and their families.
There is a chaplain available 24
hours a day.
Child Life Therapist/Music
Therapist: two full-time Child
Life therapists, one full-time
Child Life assistant and one parttime music therapist work with
patients, parents, and siblings to
aid in the adjustment and
ongoing support associated with
diagnosis and treatment of
childhood cancer.

support to the Bone Marrow
Transplant Service.
Cancer Outreach/School Re-entry
Services
Participants: Nurse, Social Worker,
Child Life Therapist/Music Therapist
Goals/Objectives:
 Build a strong connection
between hospital, parents/child,
and the school.
 Identify hospital personnel as
liaisons to the school.
 Provide school staff important
information and allow them to
ask questions which ultimately
provides them with a better level
of comfort/understanding while
interfacing with the child and
family.
 Peers “school mates” are given
accurate information and area
able to ask questions to relieve
anxieties regarding cancer.
 Construct a support system
through the school for the patient
through peer comprehension and
support.
 Provide an opportunity for
preventive education/outreach
regarding smoking cessation and
sun exposure. These programs
are tailored to the appropriate
age group being spoken to.

Nutrition/Pharmacy Services
 Nutrition: two full-time and one
part-time registered dietician
support the nutrition needs of
the patient/family. In addition,
there is a nutrition tech that adds
support to the team.
 Pharmacy: two full-time
pharmacists and one full time
technician support the
operations of a satellite
pharmacy Monday -Friday, 7:00
a.m. to 7:30 p.m. This satellite
supports the inpatient and
outpatient areas in preparing and
dispensing chemotherapy. In
addition, one full-time
pharmacist provides clinical
consultation to the oncology
service and one full-time
pharmacist provides clinical
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The Children’s Mercy Cancer Center Holiday Hero

The Children’s Mercy Cancer Center Web site offers patient/family education, as well
as, public education regarding childhood cancer.
www.childrens-mercy.org
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CANCER REGISTRY
The Cancer Registry is a vital part of the
Cancer Care Program at Children’s Mercy
Hospital. This year’s statistics reflect the
highest number of patients ever to enter
the registry with a total of 126 patients.
From January, 1990 through December,
2003 the Cancer Registry has recorded
1,237 patients. The registry at CMH
contributes to cancer surveillance and
control by the following methods:

• Following our cancer patients
annually throughout their lifetime to
check on their health status.
• Participating in the approval process
for our facilities accreditation from
the American College of Surgeons
Commission of Cancer. The
Children’s Mercy Cancer Program
was awarded full three-year approval
at the last survey in July 2002.

• Collecting and maintaining data
on all types of malignancies.
- Data collected include: patient
demographics, cancer type and
location, stage of disease at
diagnosis, treatment received,
recurrence and follow-up
information.
• Collecting data on certain benign/
borderline conditions as approved by
the Cancer Care Committee. These
conditions are monitored because of
location or propensity to recur and/
or progress to malignancy. (see
Figure 2)
• Assigning a Class of Case according
to the criteria set forth by the
American College of Surgeon
(ACOS). This data item shows the
role that CMH plays in the patients
diagnosis and treatment.
(see Figure 2)
• Providing data to the Missouri
Central Cancer Registry, the
National Cancer Data Base, and
physicians. This data is essential in
the epidemiological study of cancer
incidence, survival, and treatment
effects on a local, state and national
level.

The most frequent diagnoses during
2003 were tumors of the central nervous
system representing 31 percent of the
annual caseload. There were 28
diagnoses of leukemia making up 22
percent of the 2003 patients. (see
Figures 1 and 4)
The geographical area of the 2003
patients coming to CMH for cancer care
included 42 different counties from three
states. Of those, there were 20 Missouri
counties, 19 Kansas counties and one
Nebraska county represented. (see Figure
5)

The most frequent
diagnoses during 2003
were tumors of the central
nervous system...
Twenty-one cancer-related deaths were
reported in 2003, seven of which were
diagnosed the same year, and most of
which were identified as tumors of the
central nervous system. (see Figure 3)
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CANCER REGISTRY
CHILDREN’S MERCY HOSPITAL CANCER
REGISTRY 2003 FREQUENCY OF DIAGNOSIS
FIGURE 1
Central Nervous System
Astrocytoma
Medulloblastoma
Glioma
Atypical Teratoid/
Rhabdoid Tumor
Ependymoma
Glioblastoma Multiforme
Germinoma
NG Germ Cell Tumor
Benign/Borderline Tumors

39 (31%)
11
5
4

Leukemia
ALL
AML

28 (22%)
23
5

Lymphoma
Non-Hodgkins
Hodgkins

Class 0 = 0 (0%)
Diagnosed at CMH – received all of first
course of treatment elsewhere.
Class 1 = 84 (67%)
Diagnosed at CMH – received all or part of
first course of treatment at CMH.

3
3
2
1
1
9

Class 2 = 16 (13%)
Diagnosed elsewhere – received all or part of
first course of treatment at CMH.

8
4
4

(6%)

Neuroblastoma

12

(10%)

Osteosarcoma

7

(6%)

Ewings Sarcoma

4

(3%)

Wilms

3

(2%)

Other
Retinoblastoma
Rhabdomyosarcoma
Hepatocellular Carcinoma
Renal Cell Carcinoma
Adenocarcinoma
Pleuropulmonaryblastoma
Clear Cell Sarcoma
Malignant Rhabdoid Tumor
Fibrosarcoma
Undifferentiated Sarcoma
Misc. Reportable Conditions

CLASS OF CASE (ACOS-COC CLASSIFICATION)
AND REPORTABLE CONDITIONS
FIGURE 2

Class 3 = 4 (3%)
Diagnosed elsewhere – received all of first
course of treatment elsewhere. Now at CMH
with recurrence, disease progression, or
subsequent treatment.
Reportable Conditions*
(Benign / Borderline) = 22 (17%)
Included in the Registry due to location of
tumor or because of its propensity to recur.
*The Cancer Care Committee has approved
the following conditions to be included in the
Registry. These conditions are collected in
addition to the histologic malignant behavior
cases.
- Borderline / Benign lesions of the
Central Nervous System
- Mesoblastic nephroma
- Teratomas, regardless of locations
- Theca cell- granulosa cell tumor
- Lymphoproliferative Disease
- Ganglioneuroma
- Myeloproliferative Disease
- Langerhan’s Cell Histiocytosis

25 (20%)
2
1
1
1
1
1
1
1
1
1
14
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CANCER REGISTRY
2003 MORTALITY DATA
FIGURE 3
Central Nervous System
Medulloblastoma
Ependymoma
Glioblastoma Multiforme
Atypical Teratoid/
Rhabdoid Tumor
Brain Stem Glioma
Leukemia
ALL
AML
Juvenile Myelomonocytic
Leukemia

AML PATIENTS
5 YEAR SURVIVAL COMPARISON RATE
7

SEER 5-YEAR RELATIVE SURVIVAL RATES (PERCENT)
AGES 0-19* - 1995-2000 = 49.5%

1
2
1

CMH 5- YEAR KAPLAN-MEIER ADJUS TED SURVIVAL RATES
(PERCENT) AGES 0-20** - 199 4-2003 = 47.5%

2
1

AML - 1994-2003 - Children’s Mercy

5
1
3
1

Rhabdomyosarcoma

2

Neuroblastoma

2

Ewings Sarcoma

1

Osteosarcoma

1

Malignant Rhabdoid Tumor

1

Lymphoepithelial Carcinoma

1

Myeloproliferative Disorder

1

Total Number of Mortalities in 2003

*Table XXVII-8 SEER Cancer Statistics Review 1975-2000
** Cancer Registry Management: Principles and Practice- Pg
431 comparison of Relative and Kaplan-Meier Adjusted
Survival Modules
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AML: AGE AND SEX DISTRIBUTION-10 YEAR COMPARISON
YEAR

TOTAL

MALE

FEMALE

2003
2002
2001
2000
1999
1998
1997
1996
1995
1994
TOTAL

5
10
6
5
6
8
3
5
5
4
57

4
5
3
2
4
5
0
0
3
2
28

1
5
3
3
2
3
3
5
2
2
29

AGE
0-2
0
5
2
2
1
1
0
2
1
1
15

12

AGE
3-6
1
2
0
0
3
3
1
1
0
2
13

AGE
7-10
0
1
2
1
1
1
0
1
1
0
8

AGE
11-16
4
2
1
1
1
3
2
0
2
1
17

AGE
>16
0
0
1
1
0
0
0
1
1
0
4

CANCER REGISTRY
A FIVE-YEAR COMPARISON OF MOST FREQUENTLY OCCURRING DIAGNOSES
AT CHILDREN’S MERCY HOSPITAL
FIGURE 4

Total Diagnoses

CANCER CARE MAP - PATIENT ORIGIN
FIGURE 5
Cancer Care

Patient Origin – 2003
Cancer Care
Shaded by Patient Origin

Worth
Atchison

Nodaway

Scotland

Gentry

Sullivan

Andrew
Republic

Marshall

Washington

Nemaha

Brown

DeKalb

Clinton
Clay

Pottawatomie
Riley

Jackson

Ottawa
Geary

Wabaunsee

Platte
Jefferson
Leavenworth

Douglas

Dickinson

h

Johnson

Osage

Franklin

Carroll

Anderson

Lafayette

Jackson

Woodson

Allen

Wilson

Sumner

Pettis

Cowley
Chautauqua

Red Circle – 100 mile radius

Warren

St.

Cole
Morgan

Osage

Gasconade

Benton

Bates

Franklin

Miller

Linn

Maries
Camden

Crawford Washington

Hickory
Vernon

Pulaski
Polk

Neosho

Dallas

Phelps

St.

Laclede
Dent

Barton

Iro
Dade

Crawford

MontgomeryLabette

Montgomery
Callaway

Moniteau

Cedar

Elk

per

Lincoln

Cass

Butler

an

Pike
Audrain

Miami

Bourbon

Ralls

Randolph

Howard

Saline

St. Clair
Greenwood

Sedgwick

Chariton

Boone

Harvey
no

Monroe

Ray

Henry
Coffey

Lewis

Shelby

Cooper

Chase

27
10
8
4
2

Marion

Macon

Lyon

Marion

to
to
to
to
to

Caldwell

Johnson

Morris

McPherson

Wyandotte

Shawnee

Clay

Clark

Knox

Linn
Livingston

Buchanan

Saline

Daviess

Doniphan

Atchison

Cloud

Adair

Grundy

Holt

10
8
4
2
1

Schuyler

Putnam

Mercer

Harrison

Cherokee

Webster

Greene

Jasper

Wright

Texas

Lawrence
Christian

Newton

Blue Circle – 50 mile radius

Barry
McDonald

Reynolds
Shannon
Carter

Douglas
Howell

Stone
Taney

Ozark

Oregon

Ripley

•

Approximately 21 percent of the patients originate from Jackson
County, Missouri.

•

Approximately 82 percent (103) of the patients live within 100
miles of Children’s Mercy.

•

Approximately 16 percent of the patients originate from Johnson
County, Kansas.

•

Approximately 69 percent (87) of the patients live within a 50
miles of the Hospital.
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Acute Myeloid Leukemia
Leukemia is a malignant disease of the
blood-forming organ, the bone marrow.
Hallmarks of a cancer cell include a
proliferation and survival advantage
over normal cells, impaired
differentiation into a mature cell, and
the capacity for endless self-renewal.
Acute myeloid leukemia (AML) results
from an uncontrolled proliferation and
maturation block in the granulocytic or
myeloid series of cells. AML is also
known by the synonymous terms: acute
myelogenous leukemia, acute myelocytic
leukemia, acute non-lymphocytic
leukemia (ANLL) and acute myeloblastic
leukemia. AML accounts for ~15-20
percent of all leukemia in childhood,
while acute lymphoblastic leukemia
accounts for ~75 percent-80 percent. It
has a relatively high frequency in
infancy (10 per million children) and
thereafter occurs at a relatively constant
frequency (5-10 per million) into
adolescence after which its incidence
increases to where in adulthood, it is the
predominant form of acute leukemia. In
general, there is a 1/14,000 risk of
developing AML in childhood. Most
patients do not have a recognized
genetic predisposition for the

development of leukemia. However, rare
heritable disorders known to predispose
children to leukemia include Fanconi
anemia, Bloom syndrome, ataxia
telangiectasia, Kostmann syndrome, and
others. Individuals with Down
syndrome are 14-20 times more likely to
develop acute leukemia than children in
the general population. While, after age
5 years, the overall ratio of AML to ALL
is the same for DS children as for
children in the general population,
before 5 years of age AML is 46x more
common in the DS child. In addition to
this increased incidence of leukemia,
newborns with Down syndrome may
show a transient myeloproliferative
disorder (TMD) that is clinically
indistinguishable from leukemia. In
contrast to true leukemia, the TMD
usually spontaneously regresses within
one to two months. Some of these
children (30 percent) will later develop
true leukemia.
Acute myeloid leukemias are classified
by the morphologic characteristics of the
cells and by genetic abnormalities. The
FAB classification shown in Table 1
classifies subtypes of AML by cell

TABLE 1
French American and British (FAB) Classification

Enzyme Reaction Pattern in Blasts

FAB Subtypes
•
M0 undifferentiated
•
M1 Minimally differentiated
•
M2 Differentiated
•
M3 Promyelocytic
•
M4 Myelomonocytic
•
M4eo Myelomoncytic w/ abnormal
eosinophils
•
M5 Monocytic / monoblastic
•
M6 Erythrocytic
•
M7 Megakaryocytic

MPO
+
+
+
+

Butyr ate
+

+
-(+)
+
-

+
++
-(+)
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+(-)
+
-(+)
+
+
-
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differentiation, immunohistochemical
staining characteristics, and lineage of
the cell, e.g., granulocytic, monocytic,
erthryocytic, megakaryocytic.

and t(9;11).
Unfavorable
cytogenetic
abnormalities
include
monosomy
7, other
11q23
abnormalities,
Figure 1 - 45,X,and other
Y,t(8;21)(q22;q22),del(9)(q22q34)
rare
Favorable prognosis karyotype.
recurrent
translocations. All other abnormalities
and a normal karyotype are included in
an intermediate prognostic group, e.g.,
+8, +21. (Figure 1) Not only do these
identify prognosis, but they also identify
the etiologies of the leukemia. By

Table 2 lists the most common recurrent
chromosomal and genetic abnormalities
and their clinical significance.
Cytogenetics at the time of diagnosis is
widely recognized as one of the most
important prognostic determinants in
AML. Approximately 75-80 percent of
cases show clonal chromosome
abnormalities at diagnosis. Correlation
of chromosome abnormality with overall
survival and event free survival finds a
favorable prognostic impact for patients
with inv(16)/t(16;16), t(8;21), t(15;17),

TABLE 2
RECURRENT CHROMOSOME ABNORMALITIES IN CHILDHOOD MYELOID DISORDERS
Chromosome
Abnormality

Genes Involved

FAB Subtype

Incidence

Prognosis

Comment

t(8;21)(q22;q22)

ETO/AML1

AML-M2

10-15%

Good

Older age, males, extramedullary tumors

t(15;17)(q22;q21)

PML/RARA

AML-M3

10-12%

Good

Older age, responsive to ATRA

inv(16)/t(16;16)

CBFB/MYH11

AML-M4eo

6-10%

Good

Increased risk of CNS disease/relapse

t(11q23;v)*

MLL

10-13%

t(9;11)(p22;q23)

AF9/MLL

AML-M4/M5
t-AML
AML-M5a

~5%

Poor
Poor
Good

t(1;22)(p13;q13)

OTT/MAL

AML-M7

<1%

Poor

Infants, high WCC, CNS & skin disease
Epipodophyllotoxin exposure
Clinically indistinguishable from other MLL
rearrangement
Infants

AML
1 o MDS
t-AML
Aplastic anemia
JMML
AML

4-7%
50-60%
5-7%
1-2%
6-24%
5-10%

Poor
Poor
Poor
Poor

-7
-7 / 7q-7 / 7q-7
-7
+8

Intermed

7q- often found in complex karyotype
Alkylating agent exposure
Risk of transformation to leukemia
Young age, favorable with BMT
Often with other chromosome abnormalities

FAB, French-American-British (classification); AML acute myelocytic leukemia; t-AML therapy-related AML; ATRA
all-trans retinoic acid;
MDS myelodysplastic syndrome; AA aplastic anemia; JMML juvenile myelomonocytic leukemia; CNS central
nervous system;
WCC white cell count
*All translocations involving 11q23, MLL gene rearrangement with chromosomes other that chromosome 9
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placement of genes in abnormal
locations by translocation or the
elimination of normal genes by deletion,
the normal control mechanisms of
cellular proliferation are missing which
in turn results in the uncontrolled
proliferation of the cells, or leukemia.
Of the clonal
chromosome
abnormalities detected
at diagnosis, ~55-60
percent are the
recognized recurrent
abnormalities
mentioned. The
majority of these
abnormalities may also
be detected using a
molecular cytogenetic
method, fluorescence in
situ hybridization
(FISH). This method
utilizes DNA probes for
the specific abnormality
or translocation under
investigation. For
patients with one of
these abnormalities
detected at diagnosis,
FISH is utilized for
post-therapy and post
transplantation
monitoring of disease
status. (Figures 2 and 3)
Secondary AML in
children previously
treated for other types
of malignant disease is
rare, but of increasing
concern due to the high
cure rate and long life

expectancy for children with cancer.
Chromosome abnormalities associated
with previous treatment include
monosomy 7, 7q deletion, t(8;21),
inv(16), 11q23, and 21q22 abnormalities.
Chromosome 11q23 abnormalities are
associated with exposure to the
epipodophyllotoxins such as etoposide
(VP16) and
chromosome 7
abnormalities are
associated with
exposure to alkylating
agents. A recent study
correlated the risk of
epipodophyllotoxinrelated AML with the
schedule of drug
Figure 2. 46,XX,t(9;11)(p22;q23)
administration and not
Favorable prognosis karyotype.
with the cumulative
drug dose. Patients
with secondary AML
whose cells show the
t(8;21) or inv(16) fare
better than patients
with -7, 7q-, 11q23 and
21q22 abnormalities.

Figure 3. FISH with MLL gene probe;
located on chromosome 11 at band q23.
Left metaphase picture shows a red/
green signal on the normal chromosome
11, a green signal on the abnormal
chromosome 11, and a red signal on the
abnormal chromosome 9. This signal
pattern confirms the t(9;11) seen in the
karyotype in Figure 2 interrupts the MLL
gene. Upper right shows the same
interruption of the MLL gene in an
interphase nucleus with the red and
green signals separated. The lower right
shows two normal MLL gene signals.
Interphase nuclei are used to assess
presence of the clone following therapy
or transplantation.
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Myelodysplastic
syndrome (MDS), a
clonal disorder
characterized by
ineffective
hematopoiesis,
morphologic
abnormalities, and
relatively low
percentages of blasts, is
rare in childhood with
an annual incidence of
4 per million. The FAB
classification of MDS
comprises five
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subgroups: RA, RARS, RAEB, RAEB in
transformation, and pediatric JMML. A
new classification system (WHO) has
redefined acute myeloid leukemia as a
myeloid neoplasia with 20 or more
percent blasts in the marrow, thereby
eliminating the RAEB-T subgroup. Loss
of chromosome 7, either as monosomy 7
or deletion 7q, is the most common
cytogenetic abnormality in childhood
MDS. Monosomy 7 or 7q deletion
occurs in 30 percent of children with
MDS and ~5 percent of children with
AML. Monosomy 7 as the sole
chromosome abnormality was associated
with an overall 3-year survival of 56
percent in patients with MDS compared
with a 3-year OS of 13 percent in those
with AML. For most children with
MDS, ie, those with RAEB ±T, therapy is
identical to those with AML.

have occult disease that can lead to
relapse. Remission and cure is achieved
only through intensive therapy that is
only exceeded in toxicity by bone
marrow transplantation. For this reason,
children undergoing therapy for AML
must remain hospitalized for weeks at a
time, extending from each of their
chemotherapy administrations until
their white blood counts recover.
Through this extreme caution, treatment
related mortality (TRM) rates throughout
North America have fallen by half, from
approximately 15 percent to now 7
percent. Therapy typically consists of 45 intensive courses of therapy extending
over approximately 6-8 months
depending upon the time it takes each
child to recover from each course.
Clinical trials performed in the 1990’s
from COG, and on which children from
CMH participated, showed that
utilization of a bone marrow transplant
from an HLA matched sibling conveyed
a 10-15 percent improved survival rate.
For the 20-25 percent of children who
have this option, it is typically
performed after 2-4 cycles of
chemotherapy. As of yet, for those
without a sibling donor, the increased
TRM that comes with unrelated donor
transplant or a mismatched related
donor transplant exceeds any
improvement in relapse rates. These
types of transplants are reserved for
those who relapse and in whom cure
without transplant is rare.

A successful outcome, ie, cure, for
children with AML continues to be a
difficult challenge with an overall longterm survival only recently approaching
50 percent (note among all children with
cancer, there is a combined cure rate
now in excess of 70 percent). This
however, is a 100 percent improvement
over cure rates of the 1980’s which were
at best 20-25 percent. This has come
from collaborative efforts of
organizations, such as the National
Cancer Institute’s Children’s Oncology
Group of which Children’s Mercy
Hospital is a major institution among
over 230 programs. COG is the largest
childhood cancer program in the world.
Complete remission is achieved in >7080 percent of children with AML after
one or two courses of chemotherapy, but
approximately half of these patients

Careful monitoring of the response to
chemotherapy allows the caregiver to
further determine / refine prognosis and
subsequently to tailor therapy to the
individual patient. Follow-up bone
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marrow morphological examination
under study including multiparameter
assesses treatment response and
flow cytometry and PCR studies for such
evaluates the percentage of leukemic
markers as Flt3-ITD, both of which in
blasts remaining in the marrow. The
early study have been significant
burden of disease as evaluated by
prognostic indicators.
morphologic examination 7, 14, and 28
days after induction therapy correlates
Advances in therapy for children with
with outcome. Cytogenetic and FISH
cancer show that we are truly on the
studies assess the presence or absence of threshold of a new millennium. Two of
any clonal chromosome
these advances are the
abnormality detected at
use of monoclonal
diagnosis. For those
antibodies and the use
patients with
of protein or kinase
abnormalities
inhibitors. Monoclonal
detectable by molecular
antibodies, based upon
DNA probes, FISH is a
techniques that
highly sensitive (0.5
identified that leukemia
percent) method for
cells have unique
detecting low levels of
surface markers that can
residual disease. FISH
serve as targets for
Figure 4. 45,XX,-7 Unfavorable prognosis
is particularly helpful
antibodies that are
karyotype.
in patients who have
designed to carry
undergone an opposite
chemotherapy agents
sex donor
directly to the cancer
transplantation. In
cell. This therapy, now
addition to assessing
at the phase where it is
engraftment status with
to be fully tested in
sex chromosome DNA
children to determine
probes, the sex
whether it truly
chromosome probes can
improves cure rates,
be combined with
offers a new approach
probes specific for the
to our traditional
diagnostic clone to
methods of giving
Figure 5. FISH using probes for the X
detect very low levels
chemotherapy that go to
chromosome (aqua) and chromosome 7
(0.001-0.00005) of
all cells in our body
centromere (green) and chromosome 7
long arm (red). The upper left shows a
residual disease in host
(but fortunately affect
nucleus with two normal chromosomes 7;
cells (Figures 4 and 5).
cancer cells more
lower left shows a nucleus with one
These newer
adversely). This trial,
chromosome 7 (monosomy 7), the upper
techniques, performed
to be performed in the
and lower right shows two nuclei with
two chromosomes X and one
at CMH, allow betterCOG, is being led by
chromosome 7 (female cells with
tailored regimens to the
Children’s Mercy
monosomy 7). This method detects host
patient’s needs.
investigators.
cells with the clonal abnormality after
opposite sex donor transplantation.
Additional methods are
Subsequent to the full
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genetic mistake. For each cancer, there
may be dozens of different mistakes that
can occur that lead to the same cancer,
as is seen in AML. For AML, several
specific agents are under study in the
earliest phases of human testing, ie, to
first determine their safety before being
fully tested. It is anticipated that as
further discoveries are made in better
understanding the genetic mistakes that
create cancers, there will be further
development of agents in this new class
of drugs that will revolutionize the care
and the cure of childhood AML.
However, until that time occurs which
may still be more than a decade away,
we continue to work to improve cure
rates for our young patients with AML,
either through better traditional agents
or through better techniques of reducing
complications.

mapping of the human genome,
researchers (such as those at Children’s
Mercy including Peter Rogan, PhD, who
is close to identifying the gene that
confers the higher risk of leukemia upon
children with Down Syndrome) are now
leading the field toward the use of new
agents that are more specific and safer.
These agents are aimed at the abnormal
proteins (kinases) that are created by the
genetic mistakes that are found in cancer
cells. In Chronic Myelogenous
Leukemia (CML), imatinib, the first agent
in this new class of drugs has
dramatically changed the face of therapy,
taking a disease that was only curable
with bone marrow transplant, to a
disease that can be placed in full
remission by the use of this single agent
without any of the side effects seen with
traditional chemotherapy. These agents
are uniquely developed for each type of

Children’s Mercy researchers are highly active in the search for better cures in
childhood AML, either through the reduction in side effects or with the use of newer
techniques and agents. The following is a sample of the recent and current work
underway by these investigators.
National Clinical & Laboratory AML Trials with a CMH Investigator*
Children’s Cancer Group CCG-2951: Acute Myeloid Leukemia Salvage Therapy for Patients in First
Relapse or Who Fail to Achieve an Initial Remission or Who Develop Acute Myeloid Leukemia as a
Second Malignant Neoplasm
Children’s Cancer Group CCG-B957: Localization of genes predisposing to acute leukemia in Down
Syndrome
Children’s Oncology Group COG-A2971: Treatment of Children with Down’s Syndrome and AML,
MDS, and Transient Myeloproliferative Disorder
Children’s Cancer Group CCG-E23: Children with Down Syndrome <19yrs Newly Diagnosed with
Leukemia between 1/1/97 and 12/31/01
Children’s Oncology Group COG-AAML0431: The Treatment of Down Syndrome Children with
Acute Myeloid Leukemia and‘Myelodysplastic Syndrome under the Age of 4 Years
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Children’s Oncology Group COG-AAML0531: Phase III Randomized Trial of Gemtuzumab
Combined with Conventional Chemotherapy for de novo Acute Myeloid Leukemia in Children
*

Either as a study chair or as a study committee member.

CMH AML Publications
PK Rogan, P Close, JL Blouin, JR Seip, L Gannutz, RL Ladda, and SE Antonarakis
(1995) Duplication and loss of chromosome 21 in two children with Down syndrome and acute
leukemia. Am J Med Genet 59(2): 174-81.
PK Rogan, DW Sabol, and HH Punnett. (1999) Maternal uniparental disomy of chromosome 21 in
a normal child. Am J Med Genet, Mar 1999; 83(1): 69-71.
Gamis A, Howell B, DeSwarte J, Feusner J, Woods W. (2000) “Incidence and impact of alpha
streptococcal infections in a prospective childhood AML trial, CCG 2891 - A report from the
Childrens Cancer Group”, Journal of Clinical Oncology, 18:1845-1855.
Sandler ES, Hagg R, Mustafa MM, Gamis A, Kamani N, Wall D. (2000) “Hematopoietic stem cell
transplantation with a conditioning regimen of busulfan, cyclophosphamide and etoposide for
children with acute myelogenous leukemia (AML): A phase I study of the Pediatric Blood and
Marrow Transplant Consortium”, Medical and Pediatric Oncology, 35(4):403-409.
Gamis A, Hilden J. (2002) “Transient Myeloproliferative Disorder A Disorder with too little Data
and many Unanswered Questions: Does It Contain an Important Piece of the Puzzle to
Understanding Hematopoiesis and AML?” J Ped Hemat Oncol, 24(1):2-5.
Mundshau G, Gurbuxani S, Gamis A, Green M, Arceci R, Crispino J. (2003) “Mutagenesis of
GATA1 is an initiating event in Down syndrome leukemogenesis”, Blood, 101(11): 4298-4300. Prepublished Online – Jan 30, 2003.
Gamis A, Woods W, Alonzo T, Buxton A, Lange B, Barnard D, Gold S, Smith F (2003) “Increased
Age at Diagnosis Has a Significantly Negative Effect on Outcome in Children with Down Syndrome
and Acute Myeloid Leukemia—A Report from the Children’s Cancer Group Study, CCG-2891",
Journal of Clinical Oncology, 21(18):3415-3422, prepublished online – Aug 1, 2003.
Wells, R, Adams M, Alonzo T, Arceci R, Buckley J, Buxton A, Dusenbery K, Gamis A, Masterson M,
Vik T, Warkentin P, Whitlock J. (2003) “Mitoxantrone and Cytarabine Induction, High Dose
Cytarabine and Etoposide Intensification for Pediatric Patients with Relapsed or Refractory Acute
Myeloid Leukemia: Children’s Cancer Group Study 2951", Journal of Clinical Oncology,
21(15):2940-47.
Greene M, Mundshau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino
J. (2003) “Mutations in GATA1 in both Transient Myeloproliferative Disorder and Acute
Megakaryoblastic Leukemia of Down syndrome”, Blood Cells, Molecules, and Diseases, 31(3):3516.
Gamis A. (2005) “Acute Myeloid Leukemia and Down Syndrome – Evolution of Modern Therapy,
State of the Art Review”, Pediatric Blood & Cancer, 44(1): 13-20, prepublished online – Aug 24,
2004.
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